Cyclerion Therapeutics (NASDAQ:CYCN) Trading Down 1.6% – Time to Sell?

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN)’s stock price dropped 1.6% during trading on Wednesday . The company traded as low as $3.60 and last traded at $3.63. 11,369 shares were traded during trading, a decline of 47% from the average daily volume of 21,285 shares. The stock had previously closed at $3.69.

Analyst Ratings Changes

Separately, Weiss Ratings raised Cyclerion Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, April 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Cyclerion Therapeutics Stock Down 1.6%

The firm’s fifty day simple moving average is $3.30 and its two-hundred day simple moving average is $2.50. The firm has a market cap of $15.72 million, a PE ratio of -2.67 and a beta of 1.74.

Cyclerion Therapeutics (NASDAQ:CYCN) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($17.20) by $16.44. Cyclerion Therapeutics had a negative return on equity of 62.10% and a negative net margin of 170.11%. As a group, analysts anticipate that Cyclerion Therapeutics, Inc. will post -1.2 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cyclerion Therapeutics stock. Two Sigma Investments LP bought a new position in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned about 0.40% of Cyclerion Therapeutics at the end of the most recent quarter. 75.62% of the stock is currently owned by hedge funds and other institutional investors.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.